A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants

Inclusion criteria

• Are overtly healthy males or females, as determined by medical history and physical examination
• Women not of child-bearing potential
• Menopausal women
• Have a body mass index of 18.0 to 29.0 kilograms per square meter (kg/m^2)

Exclusion criteria

• Women who are lactating
• Have previously completed or withdrawn from this study or any other study investigating baricitinib
• Currently enrolled in, have completed or discontinued within the last 90 days from a clinical trial involving an investigational product
• Have a pulse rate less than 50 beats per minute (bpm) at screening
• Have a current or recent history (less than 30 days prior to screening and/or less than 45 days prior to Day -1) of a clinically significant bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
• Have an absolute neutrophil count less than 2000 cells/microliter (2×10^9/liter) at screening or Day -1
• Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
• Have been exposed to a live vaccine within 12 weeks prior to the first dose or expected to need/receive a live vaccine
• Intend to use over-the-counter or prescription medication and/or herbal supplements within 14 days prior to dosing and during the study
• Have used or intend to use any drugs or substances that are known to be substrates, inducers, or inhibitors of P-glycoprotein (P-gp) within 30 days prior to dosing and throughout the study
• Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior to the first dose